Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis
Jackie Trink, Ifeanyi Kennedy Nmecha, Katrine Pilely, Renzhong Li, Zi Yang, Sydney Kwiecien, Melissa MacDonald, Bo Gao, Mariam A. Mamai, Chao Lu, Urooj F. Bajwa, Nikhil Uppal, James C. Fredenburgh, Masao Kakoki, Salvatore V. Pizzo, Anthony F. Rullo, Matthew B. Lanktree, Jeffrey I. Weitz, Yaseelan Palarasah, Joan C. Krepinsky
Jackie Trink, Ifeanyi Kennedy Nmecha, Katrine Pilely, Renzhong Li, Zi Yang, Sydney Kwiecien, Melissa MacDonald, Bo Gao, Mariam A. Mamai, Chao Lu, Urooj F. Bajwa, Nikhil Uppal, James C. Fredenburgh, Masao Kakoki, Salvatore V. Pizzo, Anthony F. Rullo, Matthew B. Lanktree, Jeffrey I. Weitz, Yaseelan Palarasah, Joan C. Krepinsky
View: Text | PDF
Research Article Nephrology Therapeutics

Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis

  • Text
  • PDF
Abstract

We recently showed that cell surface translocation of the endoplasmic reticulum–resident protein GRP78, when bound by activated α 2-macroglobulin (α2M*), induces pro-fibrotic responses in glomerular mesangial cells in response to high glucose and regulates activation of the pro-fibrotic cytokine transforming growth factor-β1 (TGF-β1), implicating a pathogenic role in glomerulosclerosis. Interstitial fibrosis, largely mediated by proximal tubular epithelial cells (PTEC) and renal fibroblasts, develops later in kidney disease and correlates with functional decline. Here we investigated whether interstitial fibrosis was mediated by cell surface GRP78 (csGRP78)/α2M*. High glucose and TGF-β1 increased csGRP78 and α2M* in PTEC and renal fibroblasts, and their inhibition prevented fibrotic protein production. Interestingly, for TGF-β1, this depended on inhibition of noncanonical signaling through YAP/TAZ, with Smad3 activation unaffected. In vivo, type 1 diabetic Akita mice overexpressing TGF-β1 were treated with either a neutralizing antibody for csGRP78 (C38) or α2M* (Fα2M) or an inhibitory peptide blocking csGRP78/α2M* interaction, and mice with unilateral ureteral obstruction were treated with Fα2M or inhibitory peptide. Consistently, inhibition by antibody or peptide attenuated fibrosis and pro-fibrotic signaling. These findings show an important role for csGRP78/α2M* in mediating tubulointerstitial fibrosis in both diabetic and nondiabetic kidney disease and support their inhibition as a potential antifibrotic therapeutic intervention.

Authors

Jackie Trink, Ifeanyi Kennedy Nmecha, Katrine Pilely, Renzhong Li, Zi Yang, Sydney Kwiecien, Melissa MacDonald, Bo Gao, Mariam A. Mamai, Chao Lu, Urooj F. Bajwa, Nikhil Uppal, James C. Fredenburgh, Masao Kakoki, Salvatore V. Pizzo, Anthony F. Rullo, Matthew B. Lanktree, Jeffrey I. Weitz, Yaseelan Palarasah, Joan C. Krepinsky

×

Figure 3

Smad3 activation by high glucose, but not by TGF-β1, is mediated by csGRP78/α2M*.

Options: View larger image (or click on image) Download as PowerPoint
Smad3 activation by high glucose, but not by TGF-β1, is mediated by csGR...
High glucose– (30 mM, 48 hours) induced activation of Smad3 (measured as phosphorylation at Ser473/475) was prevented by csGRP78 inhibition in PTEC (n = 3–4) (A) and renal fibroblasts (n = 5) (B). Similarly, α2M* inhibition attenuated Smad3 activation by high glucose with either neutralizing antibody (n = 6 PTEC and 4 renal fibroblasts) (C = PTEC and D = renal fibroblasts) or inhibitory peptide (n = 4–5 PTEC and 3–4 renal fibroblasts) (E = PTEC and F = renal fibroblasts). In both PTEC and renal fibroblasts, csGRP78 (C38, 10 μg) did not prevent TGF-β1– (5 ng/mL, 48 hours) induced Smad3 activation (n = 4 and 6) (G and J, respectively). TGF-β1–induced Smad3 activation was also not prevented by α2M* inhibition (Fα2M, 10 μg) in PTEC or renal fibroblasts (n = 6 for both) (H and K, respectively). We confirmed these results using the Smad3-mediated reporter CAGA12-luciferase. TGF-β1-induced luciferase activation was not prevented by csGRP78 inhibition in either PTEC or renal fibroblasts (n = 8 for both) (I and L, respectively). Similarly, inhibition of α2M* did not prevent activation by TGF-β1 (I and L, respectively) (0.05 ng/mL, 24 hours, n = 8 for both) (*P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001; Kruskal-Wallis test used for CAGA12-luciferase in K).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts